{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:26:44Z","timestamp":1759778804992,"version":"3.41.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T00:00:00Z","timestamp":1470441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00228-016-2111-4","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T04:08:47Z","timestamp":1470456527000},"page":"1335-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson\u2019s patients"],"prefix":"10.1007","volume":"72","author":[{"given":"M","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Magistrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Cantello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Riboldazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,6]]},"reference":[{"issue":"Pt 4","key":"2111_CR1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon G, Mahieux F, Huon R, Zi\u00e9gler M (2000) Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733\u2013745","journal-title":"Brain"},{"key":"2111_CR2","unstructured":"Ravina, B.; Marder, K.; Fernandez, HH., et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS\/NIMH work group"},{"issue":"1","key":"2111_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-015-1400-x","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Hasan A, H\u00f6glinger GU (2016) Psychosis in Parkinson\u2019s disease: identification, prevention and treatment. J Neural Transm (Vienna) 123(1):45\u201350","journal-title":"J Neural Transm (Vienna)"},{"issue":"8","key":"2111_CR4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH (2008) Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: a review. Drugs Aging 25(8):665\u2013682","journal-title":"Drugs Aging"},{"key":"2111_CR5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 70:734\u2013738","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2111_CR6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","volume":"84","author":"CH Williams-Gray","year":"2013","unstructured":"Williams-Gray CH, Mason SL, Evans JR, et al. (2013) The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84(11):1258\u20131264","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 2","key":"2111_CR7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/brain\/awm313","volume":"131","author":"CH Williams-Gray","year":"2008","unstructured":"Williams-Gray CH, Hampshire A, Barker RA, Owen AM (2008) Attentional control in Parkinson\u2019s disease is dependent on COMT val 158 met genotype. Brain 131(Pt 2):397\u2013408","journal-title":"Brain"},{"key":"2111_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fneur.2014.00224","volume":"5","author":"F De Marchi","year":"2014","unstructured":"De Marchi F, Carecchio M, Cantello R, Comi C (2014) Predicting cognitive decline in Parkinson\u2019s disease: can we ask the genes? Front Neurol 5:224","journal-title":"Front Neurol"},{"issue":"7","key":"2111_CR9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, Mamikonyan E (2011) Kales HC patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68(7):899\u2013904","journal-title":"Arch Neurol"},{"issue":"2","key":"2111_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/pgs.09.175","volume":"11","author":"ME Arbouw","year":"2010","unstructured":"Arbouw ME, Guchelaar HJ, Egberts TC (2010) Novel insights in pharmacogenetics of drug response in Parkinson\u2019s disease. Pharmacogenomics 11(2):127\u2013129","journal-title":"Pharmacogenomics"},{"issue":"4","key":"2111_CR11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","volume":"15","author":"WL Baker","year":"2009","unstructured":"Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, Coleman CI (2009) Dopamine agonists in the treatment of early Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord 15(4):287\u2013294","journal-title":"Parkinsonism Relat Disord"},{"key":"2111_CR12","first-page":"CD006564","volume":"2","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. (2008) Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev 2:CD006564","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2111_CR13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","volume":"55","author":"RA Sweet","year":"1998","unstructured":"Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST (1998) Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol 55(10):1335\u20131340","journal-title":"Arch Neurol"},{"issue":"2\u20133","key":"2111_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(00)00815-3","volume":"410","author":"AH Wong","year":"2000","unstructured":"Wong AH, Buckle CE, Van Tol HH (2000) Polymorphisms in dopamine receptors: what do they tell us? Eur J Pharmacol 410(2\u20133):183\u2013203","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2111_CR15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11920-003-0075-4","volume":"5","author":"TW McAllister","year":"2003","unstructured":"McAllister TW, Summerall L (2003) Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders. Curr Psychiatry Rep 5(5):400\u2013409","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"2111_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0b013e3283242f05","volume":"20","author":"B Le Foll","year":"2009","unstructured":"Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P (2009) Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 20(1):1\u201317","journal-title":"Behav Pharmacol"},{"issue":"2","key":"2111_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","volume":"58","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Burke PF, Leurgans S, et al. (2001) Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 58(2):209\u2013213","journal-title":"Arch Neurol"},{"issue":"1","key":"2111_CR18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","volume":"10","author":"AJ Makoff","year":"2000","unstructured":"Makoff AJ, Graham JM, Arranz MJ, et al. (2000) Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson\u2019s disease. Pharmacogenetics 10(1):43\u201348","journal-title":"Pharmacogenetics"},{"issue":"2\u20133","key":"2111_CR19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.psychres.2012.07.002","volume":"200","author":"M Ferrari","year":"2012","unstructured":"Ferrari M, Bolla E, Bortolaso P, et al. (2012) Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res 200(2\u20133):1014\u20131017","journal-title":"Psychiatry Res"},{"issue":"5","key":"2111_CR20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","volume":"70","author":"M Ferrari","year":"2014","unstructured":"Ferrari M, Guasti L, Maresca A, et al. (2014) Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 70(5):539\u2013547","journal-title":"Eur J Clin Pharmacol"},{"issue":"15","key":"2111_CR21","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653","journal-title":"Mov Disord"},{"issue":"10","key":"2111_CR22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.humimm.2015.09.032","volume":"76","author":"M Cosentino","year":"2015","unstructured":"Cosentino M, Ferrari M, Kustrimovic N, Rasini E, Marino F (2015) Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: a pilot study in healthy subjects. Hum Immunol 76(10):747\u2013752","journal-title":"Hum Immunol"},{"issue":"1","key":"2111_CR23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"E Pappert","year":"1999","unstructured":"Pappert E, Goetz C, Niederman F, Raman R, Leurgans S (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord 14(1):117\u2013121","journal-title":"Mov Disord"},{"issue":"4","key":"2111_CR24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"CG Goetz","year":"1995","unstructured":"Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology 45(4):669\u2013671","journal-title":"Neurology"},{"issue":"6","key":"2111_CR25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/jnnp.71.6.777","volume":"71","author":"C Holmes","year":"2001","unstructured":"Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, Lovestone S (2001) Psychosis and aggression in Alzheimer\u2019s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 71(6):777\u2013779","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2111_CR26","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.WNL.0000068009.32067.A1","volume":"60","author":"R Kaiser","year":"2003","unstructured":"Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockm\u00f6ller J (2003) L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60(11):1750\u20131755","journal-title":"Neurology"},{"issue":"1","key":"2111_CR27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2013.10.040","volume":"133","author":"VE Ortega","year":"2014","unstructured":"Ortega VE (2014) Meyers DA2. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 133(1):16\u201326","journal-title":"J Allergy Clin Immunol"},{"issue":"1\u20132","key":"2111_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jns.2011.06.019","volume":"310","author":"N Ibarretxe-Bilbao","year":"2011","unstructured":"Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E (2011) Cerebral basis of visual hallucinations in Parkinson\u2019s disease: structural and functional MRI studies. J Neurol Sci 310(1\u20132):79\u201381","journal-title":"J Neurol Sci"},{"issue":"2","key":"2111_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","volume":"10","author":"IR Edwards","year":"1994","unstructured":"Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf 10(2):93\u2013102","journal-title":"Drug Saf"},{"issue":"8","key":"2111_CR30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/GIM.0b013e31812eece0","volume":"9","author":"AC Janssens","year":"2007","unstructured":"Janssens AC, Moonesinghe R, Yang Q, Steyerberg EW, van Duijn CM, Khoury MJ (2007) The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 9(8):528\u2013535","journal-title":"Genet Med"},{"key":"2111_CR31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2016.03.005","volume":"364","author":"A Lenka","year":"2016","unstructured":"Lenka A et al. (2016 May 15) Genetic substrates of psychosis in patients with Parkinson\u2019s disease: a critical review. J Neurol Sci 364:33\u201341","journal-title":"J Neurol Sci"},{"issue":"2","key":"2111_CR32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00439-007-0453-9","volume":"123","author":"W Huang","year":"2008","unstructured":"Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, Li MD (2008) Significant association of DRD1 with nicotine dependence. Hum Genet 123(2):133\u2013140","journal-title":"Hum Genet"},{"issue":"3","key":"2111_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","volume":"12","author":"J Duan","year":"2003","unstructured":"Duan J, Wainwright MS, Comeron JM, et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205\u2013216","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2111_CR34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/syn.20672","volume":"63","author":"MM Hirvonen","year":"2009","unstructured":"Hirvonen MM, Laakso A, N\u00e5gren K, Rinne JO, Pohjalainen T, Hietala J (2009) C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63(10):907\u2013912","journal-title":"Synapse"},{"issue":"4","key":"2111_CR35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1469-1809.2010.00578.x","volume":"74","author":"G Novak","year":"2010","unstructured":"Novak G, LeBlanc M, Zai C, et al. (2010) Association of polymorphisms in the BDNF, DRD1 and DRD3 genes with tobacco smoking in schizophrenia. Ann Hum Genet 74(4):291\u2013298","journal-title":"Ann Hum Genet"},{"issue":"4","key":"2111_CR36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1530-0277.2008.00618.x","volume":"32","author":"P Batel","year":"2008","unstructured":"Batel P, Houchi H, Daoust M, Ramoz N, Naassila M, Gorwood P (2008) A haplotype of the DRD1 gene is associated with alcohol dependence. Alcohol Clin Exp Res 32(4):567\u2013572","journal-title":"Alcohol Clin Exp Res"},{"issue":"1\u20133","key":"2111_CR37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.schres.2012.08.003","volume":"142","author":"VK Ota","year":"2012","unstructured":"Ota VK, Sp\u00edndola LN, Gadelha A, dos Santos Filho AF, Santoro ML, Christofolini DM, Bellucco FT, Ribeiro-dos-Santos \u00c2K, Santos S, Mari Jde J, Melaragno MI, Bressan RA, Smith MA, Belangero SI (2012) DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs. Schizophr Res 142(1\u20133):206\u2013208","journal-title":"Schizophr Res"},{"issue":"9","key":"2111_CR38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FPC.0b013e3283050107","volume":"18","author":"AD Johnson","year":"2008","unstructured":"Johnson AD, Zhang Y, Papp AC, et al. (2008) Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 18(9):781\u2013791","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"2111_CR39","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","volume":"225","author":"K Lundstrom","year":"1996","unstructured":"Lundstrom K, Turpin MP (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225(3):1068\u20131072","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2111_CR40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000358062","volume":"69","author":"SG Kang","year":"2014","unstructured":"Kang SG, Lee BH, Lee JS, et al. (2014) DRD3 gene rs6280 polymorphism may be associated with alcohol dependence overall and with Lesch type I alcohol dependence in Koreans. Neuropsychobiology 69(3):140\u2013146","journal-title":"Neuropsychobiology"},{"key":"2111_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2013.12.018","volume":"51","author":"SC Kuo","year":"2014","unstructured":"Kuo SC, Yeh YW, Chen CY, et al. (2014) DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. Prog Neuro-Psychopharmacol Biol Psychiatry 51:1\u20138","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"6","key":"2111_CR42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ajmg.b.31084","volume":"153B","author":"J Simpson","year":"2010","unstructured":"Simpson J, Vetuz G, Wilson M, Brookes KJ, Kent L (2010) The DRD4 receptor Exon 3 VNTR and 5\u2032 SNP variants and mRNA expression in human post-mortem brain tissue. Am J Med Genet B Neuropsychiatr Genet 153B(6):1228\u20131233","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"6","key":"2111_CR43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066592","volume":"8","author":"A Vereczkei","year":"2013","unstructured":"Vereczkei A, Demetrovics Z, Szekely A, et al. (2013) Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence. PLoS One 8(6):e66592","journal-title":"PLoS One"},{"issue":"9","key":"2111_CR44","doi-asserted-by":"crossref","first-page":"RA215","DOI":"10.12659\/MSM.881925","volume":"17","author":"R Pt\u00e1cek","year":"2011","unstructured":"Pt\u00e1cek R, Kuzelov\u00e1 H, Stefano GB (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Med Sci Monit 17(9):RA215\u2013RA220","journal-title":"Med Sci Monit"},{"issue":"3","key":"2111_CR45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp.2005.065417","volume":"77","author":"AH Evans","year":"2006","unstructured":"Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, Shaw K, Zijlmans J, Lees AJ (2006) Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 77(3):317\u2013321","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2111-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:38:48Z","timestamp":1749051528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,6]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2111-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,8,6]]}}}